ASTRAZEN.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally...

Stats
Šios dienos apimtis	11 479.00
Vidutinė apimtis	20 363.00
Rinkos kapitalizacija	135.65B
EPS	INR0 ( 2024-02-08 )
Kita pelno data	( INR0 ) 2024-05-28
Last Dividend	INR16.00 ( 2023-07-14 )
Next Dividend	INR0 ( N/A )
P/E	97.08
ATR14	INR7.31 (0.13%)

Tūris Koreliacija

Ilgas: -0.24 (neutral)

Trumpas: -0.54 (weak negative)

Signal:(49.51) Neutral

AstraZeneca Pharma India Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SEYAIND.NS	0.834

10 Labiausiai neigiamai susiję koreliacijos
CONTROLPR.NS	-0.807

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AstraZeneca Pharma India Koreliacija - Valiuta/Žaliavos

0.45
( neutral )

0.36
( neutral )

0.79
( moderate )

-0.04
( neutral )

-0.27
( neutral )

-0.81
( strong negative )

AstraZeneca Pharma India Finansinės ataskaitos

Annual	2022
Pajamos:	INR10.03B
Bruto pelnas:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Pajamos:	INR10.03B
Bruto pelnas:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Pajamos:	INR8.06B
Bruto pelnas:	INR4.48B (55.63 %)
EPS:	INR24.60

FY	2021
Pajamos:	INR8.09B
Bruto pelnas:	INR4.78B (59.12 %)
EPS:	INR37.30

Financial Reports:

No articles found.

AstraZeneca Pharma India Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR8.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR16.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

AstraZeneca Pharma India Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.66 - low (54.78%) | Divividend Growth Potential Score: 2.22 - Decrease likely (55.55%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.70	2003-04-17
Last Dividend	INR16.00	2023-07-14
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR184.10	--
Avg. Dividend % Per Year	0.19%	--
Score	1.47	--
Div. Sustainability Score	4.66
Div.Growth Potential Score	2.22
Div. Directional Score	3.44	--

Next Divdend (Est)
(2024-09-25)

INR18.37 Estimate 2.96 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.47

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR1.000	0.07%
2020	INR2.00	0.08%
2021	INR2.00	0.04%
2022	INR8.00	0.26%
2023	INR16.00	0.48%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SOBHA.NS	Dividend Junior	2023-07-28	Annually	18	0.43%
MMP.NS	Dividend Junior	2023-08-18	Annually	4	0.49%
HDFC.NS	Dividend Junior	2023-05-16	Annually	23	0.85%
BHAGCHEM.NS	Dividend Junior	2023-07-27	Annually	4	0.14%
RAIN.NS	Dividend Junior	2023-05-19	Annually	18	0.39%
KIRLOSBROS.NS	Dividend Junior	2023-07-25	Annually	17	0.99%
EMMBI.NS	Dividend Junior	2023-08-04	Annually	14	0.28%
AKSHARCHEM.NS	No Dividend Player	2023-09-20	Annually	7	0.34%
SUPRAJIT.NS	Dividend Junior	2023-09-18	Semi-Annually	20	0.45%
NBIFIN.NS	Dividend Junior	2023-08-11	Sporadic	8	0.01%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.67	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.62	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	128.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
freeCashFlowPerShareTTM	9.89	2.00	5.06	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.518	1.000	4.71	4.71	[0.2 - 0.8]
operatingProfitMarginTTM	0.145	1.000	9.10	9.10	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	97.38	1.000	0.265	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.11	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
dividendYielPercentageTTM	0.295	1.500	2.63	0	[0 - 0.4]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.87	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0207	1.000	-1.984	0	[0.1 - 0.5]
Total Score				2.22

AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.